+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glioma Treatment Market by Treatment Modality, Product Type, Glioma Grade, Line of Therapy, Molecular Subtype, Patient Age, End User - Global Forecast to 2030- Product Image
Glioma Treatment Market by Treatment Modality, Product Type, Glioma Grade, Line of Therapy, Molecular Subtype, Patient Age, End User - Global Forecast to 2030- Product Image
Sale

Glioma Treatment Market by Treatment Modality, Product Type, Glioma Grade, Line of Therapy, Molecular Subtype, Patient Age, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968146
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Glioma Treatment Market grew from USD 5.29 billion in 2024 to USD 5.70 billion in 2025. It is expected to continue growing at a CAGR of 7.53%, reaching USD 8.19 billion by 2030.

Setting the Stage for Next-Generation Glioma Treatment

The complexity of glioma treatment has increased dramatically in recent years, driven by breakthroughs in molecular profiling and targeted therapeutics. As clinical trials push the envelope of immuno-oncological approaches and novel delivery systems enhance drug penetration across the blood-brain barrier, stakeholders must navigate an increasingly intricate terrain. Regulatory pathways are evolving to accelerate patient access to life-saving therapies, while health systems recalibrate budgets to balance cost and clinical efficacy.

This executive summary distills the most compelling trends, market dynamics, and strategic implications shaping the glioma treatment environment. It offers a high-level perspective on how scientific innovations intersect with policy shifts and competitive dynamics, highlighting opportunities to optimize product portfolios, form transformative partnerships, and outpace emerging competitors. Leaders in biotech, pharmaceuticals, and academia will find this synthesis invaluable for charting the next phase of growth in this critical oncology segment.

Unprecedented Changes Driving the Glioma Treatment Environment

The past five years have witnessed transformative shifts in the glioma landscape, driven by advancements in precision oncology and immunotherapy. Molecular diagnostics have transitioned from exploratory research tools to standard-of-care instruments, enabling personalized treatment regimens based on IDH mutation status, MGMT methylation, and other actionable biomarkers. These developments have empowered clinicians to stratify patients with greater accuracy and tailor interventions that improve survival and quality of life.

Simultaneously, the integration of CAR T-cell therapies and checkpoint inhibitors into clinical trial pipelines has redefined expectations for durable responses in high-grade glioma. Radiotherapy protocols have also evolved, leveraging image-guided techniques and proton therapy to minimize collateral damage to healthy brain tissue. Cross-disciplinary collaboration among neurosurgeons, medical oncologists, and radiologists has become critical to implement multimodal regimens effectively. Together, these shifts have ushered in a more dynamic, innovation-driven market, where speed to clinic and real-world evidence generation dictate competitive advantage.

Navigating the Financial Ripples of 2025 Tariff Adjustments

The introduction of new US tariffs in early 2025 has introduced cost pressures across the glioma treatment supply chain. Active pharmaceutical ingredients sourced from overseas faced increased duties, compelling manufacturers to reassess supplier contracts and explore domestic raw material production. These shifts have translated into moderate price inflation for key chemotherapeutic agents and advanced biologics, prompting payers to demand more robust health economic data to justify reimbursement.

In response, several leading companies have initiated on-shore manufacturing partnerships to mitigate exposure to trade policies, while also negotiating bulk procurement agreements to lock in favorable pricing. Health systems are intensifying their scrutiny of formulary inclusions, weighing the incremental benefit of next-generation therapies against potential budget impact. This recalibrated environment underscores the imperative for developers to demonstrate clear clinical and economic value to secure favorable market access.

Decoding Market Segments to Identify Growth Pathways

A granular understanding of market segments is essential to pinpoint where investment and innovation yield maximum returns. When examining treatment modalities, therapies span chemotherapy, immunotherapy, radiotherapy, surgery, and targeted therapy, each further subdivided to reflect their mechanistic nuances. Product types bifurcate into branded and generic offerings, with each category encompassing both biologics and small molecules. Tumor grade is a decisive factor, as high-grade gliomas like anaplastic astrocytoma and glioblastoma multiforme command distinct clinical pathways compared to low-grade variants such as diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma.

Line of therapy distinctions delineate first-, second-, and third-line applications, guiding trial design and real-world deployment. Molecular subtypes, including IDH mutant, IDH wildtype, MGMT methylation positive, and MGMT unmethylated, form the basis for enrollment criteria and label expansion strategies. Patient age segments into adult and pediatric cohorts, further refined by age brackets of 18-64, 65+, adolescents 13-17, and children 0-12, each presenting unique safety and efficacy considerations. End users range from ambulatory surgical centers and cancer research institutes to clinics and hospitals, defining distribution channels and stakeholder engagement models. By synthesizing these layered segments, decision makers can tailor clinical development, marketing, and distribution strategies to optimize patient outcomes and financial performance.

Regional Dynamics Shaping Glioma Treatment Adoption

Regional dynamics exert a profound influence on clinical adoption, reimbursement frameworks, and competitive intensity. In the Americas, expansive healthcare infrastructure and progressive regulatory agencies have accelerated the launch of novel diagnostics and therapeutics, while private-public partnerships are fueling advanced manufacturing capabilities. Shifting payer expectations, however, require comprehensive value propositions to secure favorable formulary placement.

Across Europe, the Middle East, and Africa, heterogeneous health systems pose both challenges and opportunities. Centralized approval mechanisms in the European Union facilitate faster intra-regional launches, yet individual member states maintain distinct pricing and reimbursement protocols. In the Middle East and Africa, emerging markets are increasingly investing in oncology centers of excellence, though economic variability necessitates tiered pricing models and strategic licensing agreements.

Asia-Pacific stands out for its large patient pools and government-backed precision medicine initiatives. Nations such as Japan, South Korea, and Australia have pioneered national genomic screening programs, creating fertile ground for targeted therapies. Simultaneously, cost containment policies in markets like China and India demand localized manufacturing and outcome-based contracting to ensure broad patient access.

Competitive Landscape and Strategic Positioning of Leading Players

The competitive landscape in glioma treatment is marked by intense rivalries among biotech innovators, established pharmaceutical powerhouses, and agile start-ups. Biotech firms with proprietary platforms in CAR T-cell engineering and oncolytic vaccines have carved early footholds, leveraging breakthrough designations to expedite development. Legacy pharmaceutical companies are countering through strategic acquisitions and in-licensing agreements, augmenting their pipelines with advanced immunotherapies and small molecule inhibitors targeting EGFR and VEGF pathways.

Meanwhile, contract development and manufacturing organizations are expanding capacity to accommodate cell and gene therapy demands, creating a service-centric submarket that supports the broader ecosystem. Collaborative consortia between industry and academic centers are also proliferating, focusing on translational research to bridge preclinical discoveries with clinical applications. This convergence of expertise and resources underscores the importance of strategic alliances to drive sustainable innovation and secure competitive differentiation.

Strategic Imperatives to Capitalize on Emerging Opportunities

To capitalize on the evolving glioma market, industry leaders should prioritize integrated development strategies that align molecular targeting with advanced delivery mechanisms. Investing in biomarker-driven clinical trials will provide definitive evidence of patient stratification benefits, enhancing both regulatory and payer acceptance. At the same time, forging partnerships with contract manufacturers can mitigate tariff-induced supply chain risks and ensure scalable commercial production.

On the commercial front, tailored engagement models for key physician groups and patient advocacy organizations will amplify market penetration. Implementing outcomes-based contracting across high-cost asset portfolios can address payer concerns and accelerate formulary inclusion. Finally, dedicating resources to real-world evidence generation through registries and digital health platforms will strengthen value propositions, support label expansions, and inform future R&D priorities.

Rigorous Methodology Underpinning Data Credibility

This report is grounded in a robust methodology combining primary and secondary research to ensure the highest level of data integrity. Primary insights were derived from in-depth interviews with oncologists, neurosurgeons, payers, and industry executives, as well as clinical trial investigators and regulatory specialists. Secondary research encompassed published literature, regulatory filings, conference proceedings, and proprietary databases covering trial pipelines, patent landscapes, and market access policies.

Data triangulation and cross-validation techniques were employed to reconcile divergent sources, while sensitivity analyses tested the impact of key assumptions. Geographic coverage included major markets across the Americas, Europe, Middle East & Africa, and Asia-Pacific, ensuring a comprehensive global perspective. Quality assurance protocols featured peer reviews by subject-matter experts and iterative refinements to uphold accuracy and relevance.

Bringing It All Together for Informed Decision Making

This executive summary distills critical insights into the transformative trends, financial considerations, and competitive dynamics shaping the glioma treatment market. By synthesizing segmentation analysis, regional nuances, and corporate strategies, industry stakeholders can navigate a complex environment with clarity and confidence. The recommendations provided serve as a roadmap for prioritizing investments, optimizing partnerships, and accelerating patient access to next-generation therapies.

As the field continues to evolve, sustained commitment to innovation, evidence generation, and stakeholder collaboration will determine which organizations emerge as leaders in combating this challenging disease. Armed with the insights from this report, decision makers are well positioned to drive meaningful advances in clinical outcomes and commercial success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Modality
    • Chemotherapy
      • Alkylating Agents
      • Anti-Microtubule Agents
    • Immunotherapy
      • Car T-Cell Therapy
      • Checkpoint Inhibitors
      • Vaccines
    • Radiotherapy
      • Brachytherapy
      • External Beam Radiotherapy
    • Surgery
    • Targeted Therapy
      • Egfr Inhibitors
      • Vegf Inhibitors
  • Product Type
    • Branded
      • Biologics
      • Small Molecule
    • Generic
      • Biologics
      • Small Molecule
  • Glioma Grade
    • High Grade
      • Anaplastic Astrocytoma
      • Glioblastoma Multiforme
    • Low Grade
      • Diffuse Astrocytoma
      • Oligoastrocytoma
      • Oligodendroglioma
  • Line Of Therapy
    • First Line
    • Second Line
    • Third Line
  • Molecular Subtype
    • Idh Mutant
    • Idh Wildtype
    • Mgmt Methylation Positive
    • Mgmt Unmethylated
  • Patient Age
    • Adult
      • 18-64
      • 65+
    • Pediatric
      • Adolescents 13-17
      • Children 0-12
  • End User
    • Ambulatory Surgical Centers
    • Cancer Research Institutes
    • Clinics
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novocure Ltd.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Glioma Treatment Market, by Treatment Modality
8.1. Introduction
8.2. Chemotherapy
8.2.1. Alkylating Agents
8.2.2. Anti-Microtubule Agents
8.3. Immunotherapy
8.3.1. Car T-Cell Therapy
8.3.2. Checkpoint Inhibitors
8.3.3. Vaccines
8.4. Radiotherapy
8.4.1. Brachytherapy
8.4.2. External Beam Radiotherapy
8.5. Surgery
8.6. Targeted Therapy
8.6.1. Egfr Inhibitors
8.6.2. Vegf Inhibitors
9. Glioma Treatment Market, by Product Type
9.1. Introduction
9.2. Branded
9.2.1. Biologics
9.2.2. Small Molecule
9.3. Generic
9.3.1. Biologics
9.3.2. Small Molecule
10. Glioma Treatment Market, by Glioma Grade
10.1. Introduction
10.2. High Grade
10.2.1. Anaplastic Astrocytoma
10.2.2. Glioblastoma Multiforme
10.3. Low Grade
10.3.1. Diffuse Astrocytoma
10.3.2. Oligoastrocytoma
10.3.3. Oligodendroglioma
11. Glioma Treatment Market, by Line of Therapy
11.1. Introduction
11.2. First Line
11.3. Second Line
11.4. Third Line
12. Glioma Treatment Market, by Molecular Subtype
12.1. Introduction
12.2. Idh Mutant
12.3. Idh Wildtype
12.4. Mgmt Methylation Positive
12.5. Mgmt Unmethylated
13. Glioma Treatment Market, by Patient Age
13.1. Introduction
13.2. Adult
13.2.1. 18-64
13.2.2. 65+
13.3. Pediatric
13.3.1. Adolescents 13-17
13.3.2. Children 0-12
14. Glioma Treatment Market, by End User
14.1. Introduction
14.2. Ambulatory Surgical Centers
14.3. Cancer Research Institutes
14.4. Clinics
14.5. Hospitals
15. Americas Glioma Treatment Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Glioma Treatment Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Glioma Treatment Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. F. Hoffmann-La Roche AG
18.3.2. Merck & Co., Inc.
18.3.3. Novocure Ltd.
18.3.4. Bristol-Myers Squibb Company
18.3.5. Eisai Co., Ltd.
18.3.6. Teva Pharmaceutical Industries Ltd.
18.3.7. Dr. Reddy’s Laboratories Ltd.
18.3.8. Pfizer Inc.
18.3.9. Novartis AG
18.3.10. Johnson & Johnson
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. GLIOMA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. GLIOMA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. GLIOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GLIOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 18-64, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 65+, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADOLESCENTS 13-17, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHILDREN 0-12, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 103. CANADA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 104. CANADA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. CANADA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. CANADA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 107. CANADA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 108. CANADA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. CANADA GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 110. CANADA GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 111. CANADA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 112. CANADA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 113. CANADA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 114. CANADA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 115. CANADA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 116. CANADA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 117. CANADA GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 118. CANADA GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 119. CANADA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. MEXICO GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 121. MEXICO GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 122. MEXICO GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 123. MEXICO GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 124. MEXICO GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 125. MEXICO GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. MEXICO GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 127. MEXICO GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 128. MEXICO GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 132. MEXICO GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 134. MEXICO GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 135. MEXICO GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 136. MEXICO GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. GERMANY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 207. GERMANY GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 208. GERMANY GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 209. GERMANY GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 210. GERMANY GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 211. GERMANY GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. GERMANY GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 213. GERMANY GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 214. GERMANY GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 215. GERMANY GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 216. GERMANY GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 218. GERMANY GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 219. GERMANY GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 220. GERMANY GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 221. GERMANY GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 222. GERMANY GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. FRANCE GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 224. FRANCE GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 225. FRANCE GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 226. FRANCE GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 227. FRANCE GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 228. FRANCE GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. FRANCE GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 230. FRANCE GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 231. FRANCE GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 232. FRANCE GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 233. FRANCE GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 234. FRANCE GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 235. FRANCE GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 236. FRANCE GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 237. FRANCE GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 238. FRANCE GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 239. FRANCE GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. ITALY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 258. ITALY GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 259. ITALY GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. ITALY GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. ITALY GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 262. ITALY GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. ITALY GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 264. ITALY GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 265. ITALY GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 266. ITALY GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 267. ITALY GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 268. ITALY GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 269. ITALY GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 270. ITALY GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 271. ITALY GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 272. ITALY GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 273. ITALY GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. SPAIN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 275. SPAIN GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. SPAIN GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. SPAIN GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 278. SPAIN GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 279. SPAIN GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. SPAIN GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 281. SPAIN GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 282. SPAIN GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 283. SPAIN GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 284. SPAIN GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 285. SPAIN GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 286. SPAIN GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 287. SPAIN GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 288. SPAIN GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 289. SPAIN GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 290. SPAIN GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 314. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 316. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 318. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 322. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 324. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 326. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 328. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 330. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 331. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 332. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 333. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 334. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 335. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 336. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 337. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2030 (USD MILLION)
TABLE 338. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 339. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 340. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 341. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. DENMARK GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 343. DENMARK GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 344. DENMARK GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 345. DENMARK GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 346. DENMARK GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 347. DENMARK GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 348. DENMARK GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 349. DENMARK GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 350. DENMARK GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2030 (USD MILLION)
TABLE 351. DENMARK GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2030 (USD MILLION)
TABLE 352. DENMARK GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2030 (USD MILLION)
TABLE 353. DENMARK GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE

Companies Mentioned

The companies profiled in this Glioma Treatment market report include:
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novocure Ltd.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.7 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.19 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Diffuse Intrinsic Pontine Glioma (DIPG) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Diffuse Intrinsic Pontine Glioma (DIPG) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Glioma Treatment - Global Strategic Business Report - Product Image

Glioma Treatment - Global Strategic Business Report

  • Report
  • 250 Pages
  • Global
From
Glioma Treatment Market Report 2025 - Product Image

Glioma Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Malignant Glioma Therapeutics - Global Strategic Business Report - Product Image

Malignant Glioma Therapeutics - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Glioma Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

Glioma Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From

About the Market

The Glioma Drug market is a subset of the larger Brain Cancer Drug market. Glioma is a type of brain cancer that is caused by the abnormal growth of glial cells in the brain. Treatment for glioma typically involves surgery, radiation therapy, chemotherapy, and targeted therapy. Drugs used to treat glioma include temozolomide, bevacizumab, and lomustine. Glioma drugs are typically used in combination with other treatments, such as radiation and surgery, to improve patient outcomes. The market for glioma drugs is expected to grow due to the increasing prevalence of brain cancer and the development of new treatments. Some companies in the Glioma Drug market include Novartis, Merck, Roche, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
OSZAR »